Regulation of diurnal variation of cholesterol 7alpha-hydroxylase (CYP7A1) activity in healthy subjects
Language English Country Czech Republic Media print-electronic
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
19537927
DOI
10.33549/physiolres.931753
PII: 1753
Knihovny.cz E-resources
- MeSH
- Enzyme Activation MeSH
- Anticholesteremic Agents administration & dosage MeSH
- Cholestenones blood MeSH
- Cholesterol 7-alpha-Hydroxylase metabolism MeSH
- Cholesterol blood MeSH
- Cholestyramine Resin administration & dosage MeSH
- Circadian Rhythm physiology MeSH
- Adult MeSH
- Gastrointestinal Agents administration & dosage MeSH
- Insulin blood MeSH
- Blood Glucose metabolism MeSH
- Chenodeoxycholic Acid administration & dosage MeSH
- Fatty Acids, Nonesterified blood MeSH
- Humans MeSH
- Reference Values MeSH
- Triglycerides blood MeSH
- Bile Acids and Salts metabolism MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 7 alpha-hydroxy-4-cholesten-3-one MeSH Browser
- Anticholesteremic Agents MeSH
- Cholestenones MeSH
- Cholesterol 7-alpha-Hydroxylase MeSH
- Cholesterol MeSH
- Cholestyramine Resin MeSH
- Gastrointestinal Agents MeSH
- Insulin MeSH
- Blood Glucose MeSH
- Chenodeoxycholic Acid MeSH
- Fatty Acids, Nonesterified MeSH
- Triglycerides MeSH
- Bile Acids and Salts MeSH
Cholesterol 7alpha-hydroxylase (CYP7A1), the key regulatory enzyme of bile acid synthesis, displays a pronounced diurnal variation. To better understand the regulation of CYP7A1 activity, three day-long examinations were carried out in 12 healthy men. The concentrations of 7alpha-hydroxycholest-4-en-3-one (C4), a surrogate marker of CYP7A1 activity, bile acids (BA), insulin, glucose, nonesterified fatty acids, triglycerides, and cholesterol were measured in serum in 90-min intervals from 7 AM till 10 PM. To lower and to increase BA concentration during the study, the subjects received cholestyramine and chenodeoxycholic acid (CDCA), respectively, in two examinations. No drug was used in the control examination. There was a pronounced diurnal variation of C4 concentration with a peak around 1 PM in most of the subjects. The area under the curve (AUC) of C4 concentration was five times higher and three times lower when subjects were treated with cholestyramine and CDCA, respectively. No relationship was found between AUC of C4 and AUC of BA concentration, but AUC of C4 correlated positively with that of insulin. Moreover, short-term treatment with cholestyramine resulted in about 10 % suppression of glycemia throughout the day. Our results suggest that insulin is involved in the regulation of diurnal variation of CYP7A1 activity in humans.
References provided by Crossref.org